ArticleJournal of thoracic disease2026
Development and validation of a radiomics-habitat model for preoperatively predicting poorly differentiated stage IA lung adenocarcinoma.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stage IA poorly differentiated lung adenocarcinoma has stronger invasiveness and shorter survival time. Its treatment methods are related to the survival time, and preoperative prediction can assist clinical practice in formulating personalized treatment options. The aim of this study was to develop and validate a computed tomography (CT)-based radiomics-habitat fusion model for preoperative prediction of stage IA poorly differentiated lung adenocarcinoma. Methods: A retrospective dual-center cohort of 507 patients with surgically confirmed stage IA lung adenocarcinoma was enrolled. The 419 patients from The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University (Center 1) were randomly assigned to a training cohort (n=294) and an internal test cohort (n=125), whereas 88 independent patients from Second Affiliated Hospital of Naval Medical University (Center 2) formed the external validation cohort. Tumor pathological differentiation graded by the 2021 World Health Organization (WHO) classification of thoracic tumors was set as the reference standard. Voxel-wise k-means clustering divided intratumoral regions into three distinct habitats (H1-3). Four machine learning algorithms [logistic regression, random forest, ExtraTrees, eXtreme Gradient Boosting (XGBoost)] were separately used to construct whole-tumor radiomics models, habitat subregional models and the final combined model. Model discrimination was comprehensively evaluated via area under the curve (AUC), sensitivity and specificity, etc.; calibration and clinical utility were assessed by calibration curves and decision curve analysis (DCA). SHapley Additive exPlanations (SHAP) analysis was applied to interpret feature contributions of the combined model. Results: Poorly differentiated lesions accounted for 26.2% (133/507) of all participants. In the independent external validation cohort, the combined model demonstrated robust discriminatory performance with an AUC of 0.880 [95% confidence interval (CI): 0.794-0.966], significantly outperforming single models (P<0.05). At the optimized decision threshold, the combined model achieved a sensitivity of 0.84 and a specificity of 0.81. DCA confirmed that the combined model provided substantial net clinical benefit. Conclusions: The developed and externally validated CT-based radiomics-habitat combined model serves as a promising non-invasive tool for preoperatively identifying poorly differentiated stage IA lung adenocarcinoma. Nevertheless, our external validation cohort only included 88 patients from a single independent center, which limits the generalizability of the model; further multi-center validation is warranted prior to clinical use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.